In a phase 1/2 trial, the recombinant interleukin-1 receptor antagonist anankira was safe and associated with clinically meaningful improvements in neurobehavioral and quality-of-life outcomes in patients with Sanfilippo syndrome.
- Lynda E. Polgreen
- Agnes H. Chen
- Julie B. Eisengart